Plasma β-amyloid1–42 reference values in cognitively normal subjects

In clinical practice, the use of plasma β-Amyloid1–42 (Aβ1–42) as biomarker for Alzheimer's disease is largely limited by the absence of reference values. The aim of this study was to evaluate Aβ1–42 plasma concentrations in cognitively normal subjects and to propose reference values. Plasma sa...

Full description

Saved in:
Bibliographic Details
Published inJournal of the neurological sciences Vol. 391; pp. 120 - 126
Main Authors Zecca, Chiara, Tortelli, Rosanna, Panza, Francesco, Arcuti, Simona, Piccininni, Marco, Capozzo, Rosa, Barulli, Maria Rosaria, Barone, Roberta, Cardinali, Roberta, Abbrescia, Daniela, Seripa, Davide, Brescia, Vincenzo, Logroscino, Giancarlo
Format Journal Article
LanguageEnglish
Published Elsevier B.V 15.08.2018
Subjects
Online AccessGet full text
ISSN0022-510X
1878-5883
1878-5883
DOI10.1016/j.jns.2018.06.006

Cover

Loading…
Abstract In clinical practice, the use of plasma β-Amyloid1–42 (Aβ1–42) as biomarker for Alzheimer's disease is largely limited by the absence of reference values. The aim of this study was to evaluate Aβ1–42 plasma concentrations in cognitively normal subjects and to propose reference values. Plasma samples were obtained from 245 subjects, with a wide age-range (19–89 years), enrolled at the Unit of Laboratory Medicine of the “Azienda Ospedaliera Cardinale G. Panico” (younger subjects) and from a population-based study on aging (GreatAGE study) (older subjects). Three different age-groups were established: young (≤ 34), adult (35 ≤ age ≤ 64) and old (>64). The Innogenetics Elisa kit for plasma Aβ1–42 was used for the analysis. The mean (SD) concentration of plasma Aβ1–42 was 17.65 (5.71) pg/mL. A positive trend was found in Aβ1–42 levels across the three age groups (p < .0001): young subjects showed values of Aβ1–42 significantly lower than the adult group (p < .0001) and than the old one (p < .0001 overall); no significant differences were found between the adult and the old groups (p = 1.0000). For the entire cohort the lower limit of 90% Reference Interval, double-sided, was 8.12 pg/mL (95% CI 6.77–9.45) and the upper limit was 29.00 pg/mL (95% CI 27.01–31.00). The present study proposes reference values for plasma Aβ1–42. Nevertheless, further studies are needed to confirm these results and corroborate the use of these reference values in clinical practice. •Aβ1–42 plasma levels evaluated in cognitively normal subjects.•Plasma samples obtained from 245 subjects, 19–89 years of age.•Three different age groups established: age ≤ 34 years, 35 ≤ age ≤ 64 years, age > 64.•Significant differences among the three age subgroups.
AbstractList In clinical practice, the use of plasma β-Amyloid1–42 (Aβ1–42) as biomarker for Alzheimer's disease is largely limited by the absence of reference values. The aim of this study was to evaluate Aβ1–42 plasma concentrations in cognitively normal subjects and to propose reference values. Plasma samples were obtained from 245 subjects, with a wide age-range (19–89 years), enrolled at the Unit of Laboratory Medicine of the “Azienda Ospedaliera Cardinale G. Panico” (younger subjects) and from a population-based study on aging (GreatAGE study) (older subjects). Three different age-groups were established: young (≤ 34), adult (35 ≤ age ≤ 64) and old (>64). The Innogenetics Elisa kit for plasma Aβ1–42 was used for the analysis. The mean (SD) concentration of plasma Aβ1–42 was 17.65 (5.71) pg/mL. A positive trend was found in Aβ1–42 levels across the three age groups (p < .0001): young subjects showed values of Aβ1–42 significantly lower than the adult group (p < .0001) and than the old one (p < .0001 overall); no significant differences were found between the adult and the old groups (p = 1.0000). For the entire cohort the lower limit of 90% Reference Interval, double-sided, was 8.12 pg/mL (95% CI 6.77–9.45) and the upper limit was 29.00 pg/mL (95% CI 27.01–31.00). The present study proposes reference values for plasma Aβ1–42. Nevertheless, further studies are needed to confirm these results and corroborate the use of these reference values in clinical practice. •Aβ1–42 plasma levels evaluated in cognitively normal subjects.•Plasma samples obtained from 245 subjects, 19–89 years of age.•Three different age groups established: age ≤ 34 years, 35 ≤ age ≤ 64 years, age > 64.•Significant differences among the three age subgroups.
In clinical practice, the use of plasma β-Amyloid1-42 (Aβ1-42) as biomarker for Alzheimer's disease is largely limited by the absence of reference values. The aim of this study was to evaluate Aβ1-42 plasma concentrations in cognitively normal subjects and to propose reference values.BACKGROUNDIn clinical practice, the use of plasma β-Amyloid1-42 (Aβ1-42) as biomarker for Alzheimer's disease is largely limited by the absence of reference values. The aim of this study was to evaluate Aβ1-42 plasma concentrations in cognitively normal subjects and to propose reference values.Plasma samples were obtained from 245 subjects, with a wide age-range (19-89 years), enrolled at the Unit of Laboratory Medicine of the "Azienda Ospedaliera Cardinale G. Panico" (younger subjects) and from a population-based study on aging (GreatAGE study) (older subjects). Three different age-groups were established: young (≤ 34), adult (35 ≤ age ≤ 64) and old (>64). The Innogenetics Elisa kit for plasma Aβ1-42 was used for the analysis.METHODSPlasma samples were obtained from 245 subjects, with a wide age-range (19-89 years), enrolled at the Unit of Laboratory Medicine of the "Azienda Ospedaliera Cardinale G. Panico" (younger subjects) and from a population-based study on aging (GreatAGE study) (older subjects). Three different age-groups were established: young (≤ 34), adult (35 ≤ age ≤ 64) and old (>64). The Innogenetics Elisa kit for plasma Aβ1-42 was used for the analysis.The mean (SD) concentration of plasma Aβ1-42 was 17.65 (5.71) pg/mL. A positive trend was found in Aβ1-42 levels across the three age groups (p < .0001): young subjects showed values of Aβ1-42 significantly lower than the adult group (p < .0001) and than the old one (p < .0001 overall); no significant differences were found between the adult and the old groups (p = 1.0000). For the entire cohort the lower limit of 90% Reference Interval, double-sided, was 8.12 pg/mL (95% CI 6.77-9.45) and the upper limit was 29.00 pg/mL (95% CI 27.01-31.00).RESULTSThe mean (SD) concentration of plasma Aβ1-42 was 17.65 (5.71) pg/mL. A positive trend was found in Aβ1-42 levels across the three age groups (p < .0001): young subjects showed values of Aβ1-42 significantly lower than the adult group (p < .0001) and than the old one (p < .0001 overall); no significant differences were found between the adult and the old groups (p = 1.0000). For the entire cohort the lower limit of 90% Reference Interval, double-sided, was 8.12 pg/mL (95% CI 6.77-9.45) and the upper limit was 29.00 pg/mL (95% CI 27.01-31.00).The present study proposes reference values for plasma Aβ1-42. Nevertheless, further studies are needed to confirm these results and corroborate the use of these reference values in clinical practice.CONCLUSIONThe present study proposes reference values for plasma Aβ1-42. Nevertheless, further studies are needed to confirm these results and corroborate the use of these reference values in clinical practice.
Author Tortelli, Rosanna
Arcuti, Simona
Barone, Roberta
Cardinali, Roberta
Piccininni, Marco
Logroscino, Giancarlo
Brescia, Vincenzo
Capozzo, Rosa
Zecca, Chiara
Abbrescia, Daniela
Seripa, Davide
Barulli, Maria Rosaria
Panza, Francesco
Author_xml – sequence: 1
  givenname: Chiara
  surname: Zecca
  fullname: Zecca, Chiara
  email: neurodeg.uniba@piafondazionepanico.it
  organization: Unit of Laboratory Medicine, Pia Fondazione Card.G. Panico, Tricase, Lecce, Italy
– sequence: 2
  givenname: Rosanna
  surname: Tortelli
  fullname: Tortelli, Rosanna
  organization: Unit of Neurodegenerative Disease, Department of Clinical Research in Neurology, University of Bari “Aldo Moro” at “Pia Fondazione Card. G. Panico”, Tricase, Lecce, Italy
– sequence: 3
  givenname: Francesco
  surname: Panza
  fullname: Panza, Francesco
  organization: Unit of Neurodegenerative Disease, Department of Clinical Research in Neurology, University of Bari “Aldo Moro” at “Pia Fondazione Card. G. Panico”, Tricase, Lecce, Italy
– sequence: 4
  givenname: Simona
  surname: Arcuti
  fullname: Arcuti, Simona
  organization: Unit of Neurodegenerative Disease, Department of Clinical Research in Neurology, University of Bari “Aldo Moro” at “Pia Fondazione Card. G. Panico”, Tricase, Lecce, Italy
– sequence: 5
  givenname: Marco
  surname: Piccininni
  fullname: Piccininni, Marco
  organization: Unit of Neurodegenerative Disease, Department of Clinical Research in Neurology, University of Bari “Aldo Moro” at “Pia Fondazione Card. G. Panico”, Tricase, Lecce, Italy
– sequence: 6
  givenname: Rosa
  surname: Capozzo
  fullname: Capozzo, Rosa
  organization: Unit of Neurodegenerative Disease, Department of Clinical Research in Neurology, University of Bari “Aldo Moro” at “Pia Fondazione Card. G. Panico”, Tricase, Lecce, Italy
– sequence: 7
  givenname: Maria Rosaria
  surname: Barulli
  fullname: Barulli, Maria Rosaria
  organization: Unit of Neurodegenerative Disease, Department of Clinical Research in Neurology, University of Bari “Aldo Moro” at “Pia Fondazione Card. G. Panico”, Tricase, Lecce, Italy
– sequence: 8
  givenname: Roberta
  surname: Barone
  fullname: Barone, Roberta
  organization: Unit of Neurodegenerative Disease, Department of Clinical Research in Neurology, University of Bari “Aldo Moro” at “Pia Fondazione Card. G. Panico”, Tricase, Lecce, Italy
– sequence: 9
  givenname: Roberta
  surname: Cardinali
  fullname: Cardinali, Roberta
  organization: Unit of Laboratory Medicine, Pia Fondazione Card.G. Panico, Tricase, Lecce, Italy
– sequence: 10
  givenname: Daniela
  surname: Abbrescia
  fullname: Abbrescia, Daniela
  organization: Laboratory of Epidemiology and Biostatistics, National Institute for Digestive Diseases, IRCCS “Saverio de Bellis”, Castellana, Bari, Italy
– sequence: 11
  givenname: Davide
  surname: Seripa
  fullname: Seripa, Davide
  organization: Geriatric Unit & Laboratory of Gerontology and Geriatrics, Department of Medical Sciences, IRCCS “Casa Sollievo della Sofferenza”, San Giovanni Rotondo, Foggia, Italy
– sequence: 12
  givenname: Vincenzo
  surname: Brescia
  fullname: Brescia, Vincenzo
  organization: Unit of Laboratory Medicine, Pia Fondazione Card.G. Panico, Tricase, Lecce, Italy
– sequence: 13
  givenname: Giancarlo
  surname: Logroscino
  fullname: Logroscino, Giancarlo
  email: giancarlo.logroscino@uniba.it
  organization: Unit of Neurodegenerative Disease, Department of Clinical Research in Neurology, University of Bari “Aldo Moro” at “Pia Fondazione Card. G. Panico”, Tricase, Lecce, Italy
BookMark eNqFkL1OwzAUhS1UJNrCA7BlZEnwXxxbTKiCglQJBpDYLMe5QQ6uA3FbqRvvwJvwIDwET4KrMrEw3eU7R-d-EzQKfQCETgkuCCbivCu6EAuKiSywKDAWB2hMZCXzUko2QmOMKc1Lgp-O0CTGDidCSjVG83tv4tJkX5-5WW597xry_f7BaTZACwMEC9nG-DXEzIXM9s_BrdwG_DYL_bA0PovrugO7isfosDU-wsnvnaLH66uH2U2-uJvfzi4XORBWVjmvakFJrawUHDhRjPFK8bphSjailo3lbV0J0zJhBW1ZaaFqeK3aFttSMLBsis72va9D_5ZmrfTSRQvemwD9OmqKpaRKYFIl9GKPQtqzcTDoaN3uo8YNabJueqcJ1jt9utNJn97p01joJCel1Z-09S44a_wLbP_J_gCryXtE
ContentType Journal Article
Copyright 2018 Elsevier B.V.
Copyright © 2018 Elsevier B.V. All rights reserved.
Copyright_xml – notice: 2018 Elsevier B.V.
– notice: Copyright © 2018 Elsevier B.V. All rights reserved.
DBID 7X8
DOI 10.1016/j.jns.2018.06.006
DatabaseName MEDLINE - Academic
DatabaseTitle MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic

DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1878-5883
EndPage 126
ExternalDocumentID S0022510X18302569
GroupedDBID ---
--K
--M
.1-
.FO
.~1
0R~
1B1
1P~
1RT
1~.
1~5
4.4
457
4G.
53G
5GY
5RE
5VS
7-5
71M
8P~
9JM
AABNK
AAEDT
AAEDW
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AATTM
AAXKI
AAXLA
AAXUO
AAYWO
ABBQC
ABCQJ
ABFNM
ABFRF
ABGSF
ABIVO
ABJNI
ABLJU
ABMAC
ABMZM
ABTEW
ABUDA
ACDAQ
ACGFO
ACGFS
ACIEU
ACIUM
ACRLP
ACVFH
ADBBV
ADCNI
ADEZE
ADUVX
AEBSH
AEFWE
AEHWI
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AFPUW
AFRHN
AFTJW
AFXIZ
AGCQF
AGHFR
AGUBO
AGWIK
AGYEJ
AHHHB
AIEXJ
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
AXJTR
BKOJK
BLXMC
BNPGV
CS3
EBS
EFJIC
EFKBS
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FIRID
FNPLU
FYGXN
G-Q
GBLVA
IHE
J1W
KOM
L7B
LX8
M29
M2V
M41
MO0
MOBAO
N9A
O-L
O9-
OAUVE
OP~
OZT
P-8
P-9
P2P
PC.
Q38
ROL
RPZ
SAE
SCC
SDF
SDG
SDP
SEL
SES
SPCBC
SSH
SSN
SSU
SSZ
T5K
Z5R
~G-
AACTN
AADPK
AAIAV
ABLVK
ABYKQ
AFCTW
AFKWA
AJOXV
AMFUW
DOVZS
EFLBG
LCYCR
RIG
ZA5
7X8
AGRNS
ID FETCH-LOGICAL-e1357-47b621b9c864e419334794bd398d6b8dc4fb76af36c62f35ce7d4b9ff0c563ec3
IEDL.DBID .~1
ISSN 0022-510X
1878-5883
IngestDate Thu Jul 10 18:03:18 EDT 2025
Fri Feb 23 02:33:31 EST 2024
Tue Aug 26 16:31:56 EDT 2025
IsPeerReviewed true
IsScholarly true
Keywords APP
Plasma
Biomarker
Aβ1–40
ALT
DSM-IV-TR
DP
Reference values
CDR

SD
ANOVA
CSF
Hb
IC
Aβ1–42
SP
RIs
Alzheimer's disease
IFCC
BMI
β-amyloid
CLSI
AST
AD
Aβ peptide
ESR
HOMA Index
TSH
NINCDS-ADRDA
EDTA
MCI
CV
UPDRS-III
GGT
SPs
PET
ELISA
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-e1357-47b621b9c864e419334794bd398d6b8dc4fb76af36c62f35ce7d4b9ff0c563ec3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PQID 2088296017
PQPubID 23479
PageCount 7
ParticipantIDs proquest_miscellaneous_2088296017
elsevier_sciencedirect_doi_10_1016_j_jns_2018_06_006
elsevier_clinicalkey_doi_10_1016_j_jns_2018_06_006
PublicationCentury 2000
PublicationDate 2018-08-15
20180815
PublicationDateYYYYMMDD 2018-08-15
PublicationDate_xml – month: 08
  year: 2018
  text: 2018-08-15
  day: 15
PublicationDecade 2010
PublicationTitle Journal of the neurological sciences
PublicationYear 2018
Publisher Elsevier B.V
Publisher_xml – name: Elsevier B.V
References Figurski, Waligorska, Toledo (bb0140) 2012; 8
Van Oijen, Hofman, Soares (bb0145) 2006; 5
Dubois, Feldman, Jacova (bb0050) 2014; 13
Petersen, Smith, Waring (bb0250) 1999; 56
Shaw, Vanderstichele, Knapik-Czajka (bb0080) 2011; 121
American Psychiatric Association (bb0255) 2000
Kim, Kim, Cho (bb0295) 2016; 36
Yaffe, Weston, Graff-Radford (bb0160) 2011; 305
Hertze, Minthon, Zetterberg (bb0075) 2010; 21
Newell, Hyman, Growdon, Hedley-Whyte (bb0005) 1999; 58
Solberg, Petit, International Federation of Clinical Chemistry (IFCC) (bb0190) 1988; 26
Schupf, Tang, Fukuyama (bb0270) 2008; 105
Hansson, Stomrud, Vanmechelen (bb0165) 2012; 28
Folstein, Folstein, Mchugh (bb0240) 1975; 12
Mormino (bb0320) 2014; 24
Sperling, Aisenb, Beckettc (bb0040) 2011; 7
Mckhann, Drachman, Folstein (bb0260) 1984; 34
CLSI and IFCC, C28-A3 document (bb0210) 2008; vol. 28
Lui, Laws, Li (bb0130) 2010; 20
Ruiz, Pesini, Espinosa (bb0310) 2013; 8
Bateman, Xiong, Benzinger (bb0030) 2012; 367
Solberg, Stamm, International Federation of Clinical Chemistry (IFCC) (bb0195) 1991; 29
Rissman, Trojanowski, Shaw, Aisen (bb0100) 2012; 119
Dybkaer, Solberg, International Federation of Clinical Chemistry (IFCC) (bb0205) 1987; 25
Song, Poljak, Valenzuela (bb0285) 2011; 26
Seubert, Vigo-Pelfrey, Esch (bb0015) 1996; 359
Arai, Lee, Messinger (bb0055) 1991; 30
De Souza, Lamari, Belliard (bb0095) 2011; 82
Fahn, Elton (bb0235) 1987; Vol. 2
Scafato E, Gandin C, Farchi G, I.PR.E.A Working Group et al. Italian project on epidemiology of Alzheimer's disease (I.PR.E.A.): study designand methodology of cross-sectional survey. Aging Clin. Exp. Res. 2005; 17:29–34.
Hughes, Berg, Danziger (bb0230) 1982; 140
Mckhann, Knopman, Chertkow (bb0045) 2011; 7
Vanderstichele, Bibl, Engelborghs (bb0305) 2012; 8
Roher, Esh, Kokjohn (bb0125) 2009; 5
Metti, Cauley, Ayonayon (bb0315) 2013; 27
Iwatsubo, Odaka, Suzuki (bb0020) 1993; 13
Pesaresi, Lovati, Bertora (bb0115) 2006; 27
Solberg, International Federation of Clinical Chemistry (IFCC) (bb0180) 1987; 25
Walter, Kaether, Steiner, Haass (bb0010) 2001; 11
Davatzikos, Bhatt, Shaw (bb0085) 2011; 32
Toledo, Vanderstichele, Figurski (bb0135) 2011; 122
Blennow, Mattsson, Schöll (bb0275) 2015; 36
Montenegro, De Michina, Misciagna (bb0215) 2013; 108
Hansson, Zetterberg, Vanmechelen (bb0280) 2010; 31
Fagan, Roe, Xiong (bb0120) 2007; 64
Galasko, Chang, Motter (bb0065) 1998; 55
Chouraki, Beiser, Younkin (bb0170) 2015; 11
Apollonio, Leone, Isella (bb0245) 2005; 26
Koyama, Okereke, Yang (bb0265) 2012; 69
Solberg, International Federation of Clinical Chemistry (IFCC) (bb0200) 1987; 25
Kaffashian, Tzourio, Soumare (bb0175) 2015; 36
Laird, Cai, Savonenko (bb0060) 2005; 25
Shaw, Vanderstichele, Knapik-Czajka (bb0070) 2009; 65
Maggi, Zucchetto, Grigoletto (bb0220) 1994; 6
Boparai, Korc-Grodzicki (bb0300) 2011; 78
Graff-Radford, Crook, Lucas (bb0150) 2007; 64
Villemagne, Burnham, Bourgeat (bb0035) 2013; 12
Seppala, Herukka, Hanninen (bb0155) 2010; 81
Sciacovelli, Sonntag, Padoan (bb0290) 2012; 50
Riemenschneider, Wagenpfeil, Diehl (bb0090) 2002; 58
Buchhave, Minthon, Zetterberg (bb0025) 2012; 69
Mehta, Pirttila, Mehta (bb0110) 2000; 57
Petit Clerc, Solberg, International Federation of Clinical Chemistry (IFCC) (bb0185) 1987; 25
Toledo, Shaw, Trojanowski (bb0105) 2013; 5
References_xml – volume: 24
  start-page: 300
  year: 2014
  end-page: 312
  ident: bb0320
  article-title: The relevance of beta-amyloid on markers of Alzheimer's disease in clinically normal individuals and factors that influence these associations
  publication-title: Neuropsychol. Rev.
– volume: 69
  start-page: 98
  year: 2012
  end-page: 106
  ident: bb0025
  article-title: Hansson. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia
  publication-title: Arch. Gen. Psychiatry
– volume: 82
  start-page: 240
  year: 2011
  end-page: 246
  ident: bb0095
  article-title: Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias
  publication-title: J. Neurol. Neurosurg. Psychiatry
– volume: 11
  start-page: 249
  year: 2015
  end-page: 257
  ident: bb0170
  article-title: Plasma amyloid-beta and risk of Alzheimer's disease in the Framingham heart study
  publication-title: Alzheimers Dement.
– reference: Scafato E, Gandin C, Farchi G, I.PR.E.A Working Group et al. Italian project on epidemiology of Alzheimer's disease (I.PR.E.A.): study designand methodology of cross-sectional survey. Aging Clin. Exp. Res. 2005; 17:29–34.
– volume: 122
  start-page: 401
  year: 2011
  end-page: 413
  ident: bb0135
  article-title: Factors affecting Abeta plasma levels and their utility as biomarkers in ADNI
  publication-title: Acta Neuropathol.
– volume: 7
  start-page: 263
  year: 2011
  end-page: 269
  ident: bb0045
  article-title: The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging–Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
  publication-title: Alzheimers Dement.
– volume: 58
  start-page: 1147
  year: 1999
  end-page: 1155
  ident: bb0005
  article-title: Application of the National Institute on Aging (NIA)-Reagan institute criteria for the neuropathological diagnosis of Alzheimer disease
  publication-title: J. Neuropathol. Exp. Neurol.
– volume: 119
  start-page: 843
  year: 2012
  end-page: 850
  ident: bb0100
  article-title: Longitudinal plasma amyloid beta as a biomarker of Alzheimer's disease
  publication-title: J. Neural Transm.
– volume: 29
  start-page: 531
  year: 1991
  end-page: 535
  ident: bb0195
  article-title: Approved recommendation (1991) on the theory of reference values. Part 4. Control of analytical variation in the production, transfer and application of reference values
  publication-title: J. Clin. Chem. Clin. Biochem.
– volume: 8
  start-page: 65
  year: 2012
  end-page: 73
  ident: bb0305
  article-title: Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's biomarkers standardization initiative
  publication-title: Alzheimers Dement.
– volume: 55
  start-page: 937
  year: 1998
  end-page: 945
  ident: bb0065
  article-title: High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype
  publication-title: Arch. Neurol.
– volume: 108
  start-page: 1108
  year: 2013
  end-page: 1111
  ident: bb0215
  article-title: Virus C hepatitis and type 2 diabetes: a cohort study in southern Italy
  publication-title: Am. J. Gastroenterol.
– volume: 36
  start-page: 297
  year: 2015
  end-page: 309
  ident: bb0275
  article-title: Amyloid biomarkers in Alzheimer's disease
  publication-title: Trends Pharmacol. Sci.
– volume: 31
  start-page: 357
  year: 2010
  end-page: 367
  ident: bb0280
  article-title: Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment
  publication-title: Neurobiol. Aging
– volume: 11
  start-page: 585
  year: 2001
  end-page: 590
  ident: bb0010
  article-title: The cell biology of Alzheimer's disease: uncovering the secrets of secretases
  publication-title: Curr. Opin. Neurobiol.
– volume: 359
  start-page: 325
  year: 1996
  end-page: 327
  ident: bb0015
  article-title: Isolation and quantification of soluble Alzheimer's b-peptide from biological fluids
  publication-title: Nature
– volume: 57
  start-page: 100
  year: 2000
  end-page: 105
  ident: bb0110
  article-title: Plasma and cerebrospinal fluid levels of β-amyloid proteins 1–40 and 1–42 in Alzheimer disease
  publication-title: Arch. Neurol.
– volume: 25
  start-page: 657
  year: 1987
  end-page: 662
  ident: bb0205
  article-title: Approved recommendation (1987) on the theory of reference values. Part 6. Presentation of observed values related to reference values
  publication-title: J. Clin. Chem. Clin. Biochem.
– volume: 56
  start-page: 303
  year: 1999
  end-page: 308
  ident: bb0250
  article-title: Mild cognitive impairment: clinical characterization and outcome
  publication-title: Arch. Neurol.
– volume: 69
  start-page: 824
  year: 2012
  end-page: 831
  ident: bb0265
  article-title: Plasma amyloid- β as a predictor of dementia and cognitive decline: a systematic review and meta-analysis
  publication-title: Arch. Neurol.
– volume: 32
  year: 2011
  ident: bb0085
  article-title: Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern classification
  publication-title: Neurobiol. Aging
– volume: vol. 28
  start-page: 1
  year: 2008
  end-page: 76
  ident: bb0210
  article-title: Defining, Establishing and Verifying Reference Intervals in the Clinical Laboratory: Approved Guideline
– volume: 25
  start-page: 645
  year: 1987
  end-page: 656
  ident: bb0200
  article-title: Approved recommendation (1987) on the theory of reference values. Part 5. Statistical treatment of collected reference values
  publication-title: J. Clin. Chem. Clin. Biochem.
– volume: 121
  start-page: 597
  year: 2011
  end-page: 609
  ident: bb0080
  article-title: Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI
  publication-title: Acta Neuropathol.
– volume: 105
  start-page: 14052
  year: 2008
  end-page: 14057
  ident: bb0270
  article-title: Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
– volume: 8
  year: 2013
  ident: bb0310
  article-title: Blood amyloid beta levels in healthy, mild cognitive impairment and Alzheimer's disease individuals: replication of diastolic blood pressure correlations and analysis of critical covariates
  publication-title: PLoS One
– volume: 30
  start-page: 686
  year: 1991
  end-page: 693
  ident: bb0055
  article-title: Expression patterns of beta-amyloid precursor protein (beta-APP) in neural and nonneural human tissues from Alzheimer's disease and control subjects
  publication-title: Ann. Neurol.
– volume: 367
  start-page: 795
  year: 2012
  end-page: 804
  ident: bb0030
  article-title: Dominantly inherited Alzheimer network. Clinical and biomarker changes in dominantly inherited Alzheimer's disease
  publication-title: N. Engl. J. Med.
– volume: 20
  start-page: 1233
  year: 2010
  end-page: 1242
  ident: bb0130
  article-title: AIBL research group. Plasma amyloid-beta as a biomarker in Alzheimer's disease: the AIBL study of aging
  publication-title: J. Alzheimers Dis.
– volume: 25
  start-page: 639
  year: 1987
  end-page: 644
  ident: bb0185
  article-title: Approved recommendation (1987) on the theory of reference values. Part 2. Selection of individual for the production of reference value
  publication-title: J. Clin. Chem. Clin. Biochem.
– volume: 5
  start-page: 18
  year: 2009
  end-page: 29
  ident: bb0125
  article-title: Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease
  publication-title: Alzheimers Dement.
– volume: 26
  start-page: 365
  year: 2011
  end-page: 375
  ident: bb0285
  article-title: Meta-analysis of plasma amyloid-β levels in Alzheimer's disease
  publication-title: J. Alzheimers Dis.
– volume: 28
  start-page: 231
  year: 2012
  end-page: 238
  ident: bb0165
  article-title: Evaluation of plasma Abeta as predictor of Alzheimer's disease in older individuals without dementia: a population-based study
  publication-title: J. Alzheimers Dis.
– volume: 25
  start-page: 337
  year: 1987
  end-page: 342
  ident: bb0180
  article-title: Approved recommendation (1986) on the theory of reference values. Part 1.The concepts of reference values
  publication-title: J. Clin. Chem. Clin. Biochem.
– volume: 6
  start-page: 464
  year: 1994
  end-page: 473
  ident: bb0220
  article-title: The Italian longitudinal study on aging (ILSA): design and methods
  publication-title: Aging (Milano)
– volume: 21
  start-page: 1119
  year: 2010
  end-page: 1128
  ident: bb0075
  article-title: Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years
  publication-title: J. Alzheimers Dis.
– volume: Vol. 2
  start-page: 293
  year: 1987
  end-page: 304
  ident: bb0235
  article-title: The unified Parkinson's disease rating scale
  publication-title: Recent Developments in Parkinson's Disease
– volume: 34
  start-page: 939
  year: 1984
  end-page: 944
  ident: bb0260
  article-title: Clinical diagnosis of Alzheimer's disease: report of the NINCDSADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease
  publication-title: Neurology
– volume: 305
  start-page: 261
  year: 2011
  end-page: 266
  ident: bb0160
  article-title: Association of plasma b-amyloid level and cognitive reserve with subsequent cognitive decline
  publication-title: JAMA
– volume: 25
  start-page: 11693
  year: 2005
  end-page: 11709
  ident: bb0060
  article-title: BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions
  publication-title: J. Neurosci.
– volume: 64
  start-page: 343
  year: 2007
  end-page: 349
  ident: bb0120
  article-title: Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults
  publication-title: Arch. Neurol.
– volume: 13
  start-page: 614
  year: 2014
  end-page: 629
  ident: bb0050
  article-title: Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
  publication-title: Lancet Neurol.
– volume: 65
  start-page: 403
  year: 2009
  end-page: 413
  ident: bb0070
  article-title: Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
  publication-title: Ann. Neurol.
– year: 2000
  ident: bb0255
  article-title: Diagnostic and Statistical Manual of Mental Disorders
– volume: 26
  start-page: 593
  year: 1988
  end-page: 598
  ident: bb0190
  article-title: Approved recommendation on the theory of reference values. Part 3. Preparation of individuals and collection of the specimens for the production of reference values
  publication-title: J. Clin. Chem. Clin. Biochem.
– volume: 7
  start-page: 280
  year: 2011
  end-page: 292
  ident: bb0040
  article-title: Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
  publication-title: Alzheimers Dement.
– volume: 27
  start-page: 244
  year: 2013
  end-page: 249
  ident: bb0315
  article-title: Health, aging and body composition study. The demographic and medical correlates of plasma aβ40 and aβ42
  publication-title: Alzheimer Dis. Assoc. Disord.
– volume: 12
  start-page: 357
  year: 2013
  end-page: 367
  ident: bb0035
  article-title: Australian imaging biomarkers and lifestyle (AIBL) research group. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study
  publication-title: Lancet Neurol.
– volume: 78
  start-page: 613
  year: 2011
  end-page: 626
  ident: bb0300
  article-title: Prescribing for older adults
  publication-title: Mt Sinai J. Med.
– volume: 50
  start-page: 463
  year: 2012
  end-page: 469
  ident: bb0290
  article-title: Monitoring quality indicators in laboratory medicine does not automatically result in quality improvement
  publication-title: Clin. Chem. Lab. Med.
– volume: 58
  start-page: 1622
  year: 2002
  end-page: 1628
  ident: bb0090
  article-title: Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration
  publication-title: Neurology
– volume: 27
  start-page: 904
  year: 2006
  end-page: 905
  ident: bb0115
  article-title: Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment
  publication-title: Neurobiol. Aging
– volume: 5
  start-page: 655
  year: 2006
  end-page: 660
  ident: bb0145
  article-title: Plasma Aβ(1–40) and Aβ(1–42) and the risk of dementia: a prospective case-cohort study
  publication-title: Lancet Neurol.
– volume: 64
  start-page: 354
  year: 2007
  end-page: 362
  ident: bb0150
  article-title: Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease
  publication-title: Arch. Neurol.
– volume: 36
  start-page: 2663
  year: 2015
  end-page: 2670
  ident: bb0175
  article-title: Association of plasma beta-amyloid with MRI markers of structural brain aging the 3-City Dijon study
  publication-title: Neurobiol. Aging
– volume: 81
  start-page: 1123
  year: 2010
  end-page: 1127
  ident: bb0155
  article-title: Plasma Abeta42 and Abeta40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study
  publication-title: J. Neurol. Neurosurg. Psychiatry
– volume: 5
  start-page: 8
  year: 2013
  ident: bb0105
  article-title: Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker
  publication-title: Alzheimers Res. Ther.
– volume: 8
  start-page: 250
  year: 2012
  end-page: 260
  ident: bb0140
  article-title: Improved protocol for measurement of plasma beta-amyloid in longitudinal evaluation of Alzheimer's disease neuroimaging initiative study patients
  publication-title: Alzheimers Dement.
– volume: 140
  start-page: 566
  year: 1982
  end-page: 572
  ident: bb0230
  article-title: A new clinical scale for the staging of dementia
  publication-title: Br. J. Psychiatry
– volume: 12
  start-page: 189
  year: 1975
  end-page: 198
  ident: bb0240
  article-title: “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician
  publication-title: J. Psychiatr. Res.
– volume: 26
  start-page: 108
  year: 2005
  end-page: 116
  ident: bb0245
  article-title: The frontal assessment battery (FAB): normative values in an Italian population sample
  publication-title: Neurol. Sci.
– volume: 13
  start-page: 45
  year: 1993
  end-page: 53
  ident: bb0020
  article-title: Visualization of Ab42(43) and Ab40 in senile plaques with specific ab monoclonals: evidence that the initially deposited species is Ab42(43)
  publication-title: Neuron
– volume: 36
  start-page: 595
  year: 2016
  end-page: 598
  ident: bb0295
  article-title: Reference intervals for plasma amyloid β in Korean adults without cognitive impairment
  publication-title: Ann. Lab. Med.
SSID ssj0006889
Score 2.2336237
Snippet In clinical practice, the use of plasma β-Amyloid1–42 (Aβ1–42) as biomarker for Alzheimer's disease is largely limited by the absence of reference values. The...
In clinical practice, the use of plasma β-Amyloid1-42 (Aβ1-42) as biomarker for Alzheimer's disease is largely limited by the absence of reference values. The...
SourceID proquest
elsevier
SourceType Aggregation Database
Publisher
StartPage 120
SubjectTerms Alzheimer's disease
Aβ peptide
Biomarker
Plasma
Reference values
β-amyloid
Title Plasma β-amyloid1–42 reference values in cognitively normal subjects
URI https://www.clinicalkey.com/#!/content/1-s2.0-S0022510X18302569
https://dx.doi.org/10.1016/j.jns.2018.06.006
https://www.proquest.com/docview/2088296017
Volume 391
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NSsNAEF5KBfEi_uJvWcHr2m72N8dSrFVp8WCht7CbbKClTcW2By_iO_gmPogP4ZO4kyb15yJ4TLIbwmSY-WbnmxmEzh0NhXGhJFYKTrgwDWICJknAnVZOaqvy6Q3dnuz0-c1ADCqoVdbCAK2ysP1Lm55b6-JOvZBm_WE4hBpfr4u0MaDQwkpIKOKD7nVepy-ev2geUuuw7BgOq8vMZs7xGmXQsZsuW3jC0KNvDumXac79TXsLbRZAETeX37KNKi7bQevdIhW-i67uPO6dGPz-RszER93DhH68vPIArwaHYGjk7WZ4mOEVSWj8hDNAqWM8W1g4gpntoX778r7VIcVUBOIoE4pwZWVAbRhryR33-AtqQblNWKgTaXUS89QqaVImYxmkTMROJdyGadqIhWQuZvuomk0zd4Bw7J9xlqM05v2S0mnMPKIxNEnSUAT8EAWlPKKyUNOblshb26hkh40iL8QIhBjlDDl5iPhq048_-de2s1LgkddwSFuYzE0XsMhHAT7Qourof68-RhtwBSfBVJyg6vxx4U49lJjbWq4rNbTWvL7t9D4Bj0HI5g
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JTsMwEB2VVgIuiFWU1Uhco9bxkuRYVZSULuLQSr1FduJIqdoU0fbAjX_gT_gQPoIvwU6TCLggcY0zUTQevXljzwJwq7DHhPK4JTmjFmWiaQmbcMumynUUd6WTTW8YDLk_pg8TNqlAu6iFMWmVOfZvMD1D6_xJI9dm4ylJTI2vtkXcnGDTwopxbwtqpjsVrUKt1e35wxKQuet6RdNwI1BcbmZpXtPUNO3Gmy6eZu7RN5_0C50zl9PZh72cK6LW5ncOoKLSQ9ge5LfhR3D_qKnvXKCPd0vMdeCdRPjz9Y3aqJwdgkwvb7VESYrKPKHZC0oNUZ2h5VqaU5jlMYw7d6O2b-WDESyFCXMs6khuY-mFLqeKagpmykGpjIjnRly6UUhj6XAREx5yOyYsVE5EpRfHzZBxokJyAtV0kapTQKFeoyQjakS7JseNQ6JJjcBRFHvMpnWwC30ERa2mRpdAA25QJIhNA63EwCgxyJLkeB1oKfRjM_8SuykUHmgjNzcXIlWLtXlJBwI61sLO2f8-fQ07_mjQD_rdYe8cds2KORjG7AKqq-e1utTMYiWvcsv5AoM8y5c
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Plasma+%CE%B2-amyloid1-42+reference+values+in+cognitively+normal+subjects&rft.jtitle=Journal+of+the+neurological+sciences&rft.au=Zecca%2C+Chiara&rft.au=Tortelli%2C+Rosanna&rft.au=Panza%2C+Francesco&rft.au=Arcuti%2C+Simona&rft.date=2018-08-15&rft.issn=1878-5883&rft.eissn=1878-5883&rft.volume=391&rft.spage=120&rft_id=info:doi/10.1016%2Fj.jns.2018.06.006&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-510X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-510X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-510X&client=summon